Trial Profile
Efficacy of filgrastim to prevent neutropenia in patients with lung cancer treated with cyclophosphamide, doxorubicin and etoposide chemotherapy regimens.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2014
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Amgen
- 10 Jun 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2014 Primary endpoint 'Infection-rate' has been met.